<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127187</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2020-2/MK-1</org_study_id>
    <nct_id>NCT05127187</nct_id>
  </id_info>
  <brief_title>Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center</brief_title>
  <acronym>TRODUMCRA</acronym>
  <official_title>Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <brief_summary>
    <textblock>
      People in Administrative Detention Centers often come from areas of medium or high HIV,&#xD;
      hepatitis C &amp; B endemic, and are often unaware of their serological status. Currently, HIV,&#xD;
      hepatitis C &amp; B screening is not systematically performed at the CRA of Nîmes, and when&#xD;
      performed, serological tests are used. The main disadvantage of this method is the length of&#xD;
      time it takes to obtain the results, with subjects frequently discharged before receiving&#xD;
      their results.&#xD;
&#xD;
      To improve the care of these vulnerable persons, the aim of this study is to estimate the&#xD;
      prevalence of HIV, hepatitis C and hepatitis B in the detainees of the administrative&#xD;
      detention center of Nîmes, by systematically screening with a rapid diagnosis test. In case&#xD;
      of a positive rapid diagnosis test test, a serology test will confirm the rapid diagnosis&#xD;
      test result.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HIV infection in detainees at the Nîmes Administrative Detention Center</measure>
    <time_frame>Inclusion</time_frame>
    <description>Rapid diagnosis test: Positive/negative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Hepatitis C infection in detainees at the Nîmes Administrative Detention Center</measure>
    <time_frame>Inclusion</time_frame>
    <description>Rapid diagnosis test: Positive/negative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Hepatitis B infection in detainees at the Nîmes Administrative Detention Center</measure>
    <time_frame>Inclusion</time_frame>
    <description>Rapid diagnosis test: Positive/negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of co-infections between HIV, Hepatitis C and Hepatitis B</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes or no for co-infection (HIV-Hep C / HIV-Hep B / HepC-HepB / Hiv-HepC-HepB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant country of origin</measure>
    <time_frame>Inclusion</time_frame>
    <description>Country name</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge of HIV, Hep C and Hep B status</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant previous transfusion</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intravenous drug use</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intranasal drug use</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shared drug paraphernalia</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-protected sexual activity</measure>
    <time_frame>Inclusion</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant with piercings</measure>
    <time_frame>Inclusion</time_frame>
    <description>If yes, professional done or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant with tattoos</measure>
    <time_frame>Inclusion</time_frame>
    <description>If yes, professional done or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of screening</measure>
    <time_frame>End of study (1 year)</time_frame>
    <description>% of subjects with available samples (ie no subject refusal, subjects arriving at weekend or holiday, study not offered on a weekday, technical problem with test interpretation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the screening</measure>
    <time_frame>End of study (1 year)</time_frame>
    <description>% of subjects giving samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Detainees in an Administrative Detention Center</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid diagnosis test against HIV and hepatitis C and B</intervention_name>
    <description>combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample</description>
    <arm_group_label>Detainees in an Administrative Detention Center</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All detainees arriving at the Administrative Detention Center of Nîmes from Monday to&#xD;
        Friday, and those arriving over the weekend if still present by Monday.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given their free and informed oral consent&#xD;
&#xD;
          -  Patient detained in the Nîmes Administrative Detention Center&#xD;
&#xD;
        Exclusion Criterion&#xD;
&#xD;
        • It is impossible to give the subject informed information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mélanie Kinne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélanie Kinne</last_name>
    <phone>06.84.86.60.57</phone>
    <email>melanie.kinne@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

